Abstract: The invention relates to a transdermal therapeutic system (10) comprising an active ingredient depot (11) that contains at least one active ingredient, comprising an application face which is designed for applying on a skin and which is adhesive on at least some parts of the surface, and comprising a protective film (14) which covers the application face and which comprises a first protective film part (14a) and a second protective film part (14b). The first protective film part (14a) differs from the second protective film part (14b) in terms of physical properties.

Abstract: The present invention relates to a transdermal therapeutic system for administering an active substance through the skin, comprising: a) a cover layer, b) a reservoir present on the cover layer, comprising a polymer matrix comprising the active substance, c) an adhesive layer present on the reservoir comprising a contact adhesive, and d) a removable layer present on the adhesive layer, the active substance being rivastigmine, a physiologically compatible salt, hydrate, solvate or derivative thereof, characterized in that the polymer matrix of the reservoir comprises neither hydroxyl groups nor carboxyl groups.

Abstract: Methods for producing systems for the transdermal or permucosal administration of active substances and particularly transdermal therapeutic systems (TTS), wherein the active substance depots thereof have a shape that deviates from a rectangular design.

Abstract: The present invention relates to a transdermal therapeutic system for administering an active substance through the skin, said system being suitable for an application period of at least three days, comprising the layers arranged in the following order with respect to each other: a) a cover layer, b) an active substance layer comprising a polymer matrix containing the active substance, c) an adhesive layer comprising a contact adhesive, which consists of a mixture of one or more polyisobutylenes and one or more polybutenes, and d) a pull-off layer.

Abstract: The invention relates to a transdermal therapeutic system (10) comprising an active ingredient depot (11) that contains at least one active ingredient, comprising an application face which is designed for applying on a skin and which is adhesive on at least some parts of the surface, and comprising a protective film (14) which covers the application face and which comprises a first protective film part (14a) and a second protective film part (14b). The first protective film part (14a) differs from the second protective film part (14b) in terms of physical properties.

Abstract: The invention relates to applicators (1) for implantation of an implant, having a cylinder (2) and a plunger (3) displaceably mounted therein, which plunger (3) has a pusher plunger (31) for pushing the implant out of a cannula, the cannula being mounted on a cylinder part, the cylinder part (4) being movably guided in the cylinder (2), there being provided a gear mechanism (5) which couples the plunger (3) to the cylinder part (4), a movement of the plunger (3) relative to the cylinder (2) being converted into an opposite movement of the cylinder part (4).

Abstract: The present invention relates to a transdermal therapeutic system for administering an active substance through the skin, comprising: a) a cover layer, b) a reservoir present on the cover layer, comprising a polymer matrix comprising the active substance, c) an adhesive layer present on the reservoir comprising a contact adhesive, and d) a removable layer present on the adhesive layer, the active substance being rivastigmine, a physiologically compatible salt, hydrate, solvate or derivative thereof, characterized in that the polymer matrix of the reservoir comprises neither hydroxyl groups nor carboxyl groups.

Abstract: A dermal or transdermal therapeutic system comprising a reservoir that contains at least one active substance, an active substance-permeable membrane which delimits the active-substance reservoir, and a closing layer. The closing layer is impermeable to the active substance at a temperature lying below the skin temperature while being permeable at skin temperature and above.

Abstract: The application provides an injection cannula having an implant which is detachably secured in the cannula. The application also provides a method for detachably securing an implant in an injection cannula.

Abstract: The invention relates to a system (1) for controlling an electrolytic reaction in a reaction medium, with the system (1) comprising a primary energy storage (10), an intermediate storage (30) and a control unit (50). The control unit of the system is adapted for transferring electrical energy from the primary energy storage into the intermediate storage, monitoring the state of charge of the intermediate storage, establishing an electric connection between the reaction medium and the intermediate storage when the state of charge of the intermediate storage is larger than or equal to a first threshold value, and interrupting an electric connection between the reaction medium and the intermediate storage when the state of charge of the intermediate storage is smaller than or equal to a second threshold value.

Abstract: To provide a cannula device (4) with an implant (3), the cannula device (4) is held at an extrusion die in such a way that the cannula device (4) is in contact with a sealing surface of the extrusion die. A flowable implant material is conveyed through the extrusion die into an implant channel (10) of the cannula device (4). The implant material solidifies in the implant channel, for example by means of cooling.

Abstract: Disclosed is a transdermal therapeutic system for administering an active ingredient through the skin comprising: a) a back layer, b) a reservoir on the back layer comprising b1) a first layer containing active ingredient, at least one gel former, at least one plasticizer, and a first polyisobutylene; and b2) a second layer containing active ingredient, at least one gel former, at least one plasticizer, and a second polyisobutylene, wherein the first polyisobutylene is different from the second polyisobutylene, wherein at least the first layer contains undissolved active ingredient in the form of active ingredient particles; and wherein the active ingredient is fentanyl or an analogue of the fentanyl.

Abstract: What is disclosed is a transdermal therapeutic system for administration of an active ingredient through the skin, comprising: (a) a back layer, (b) a reservoir present on the back layer, comprising the active ingredient, polyisobutylene, a gel former and a plasticizer, a portion of the active ingredient in the reservoir being present in the form of undissolved particles and the content of gel formers in the reservoir being at most 4% by weight (based in the total weight of the reservoir), the active ingredient being Fentanyl or an analogue thereof.

Abstract: A transdermal delivery system (TDS) for administering at least one active agent through the skin. The system has a first electrode, a second electrode, and a matrix located between the first and second electrodes. The TDS contains at least one active agent which is either alkaline or acidic. The system is configured such that when applying a voltage to the electrodes, the pH of the matrix, in the case of an alkaline active agent, does not exceed the pH of the active agent and, in case of an acidic active agent, does not fall below the pH of the active agent.

Abstract: A dermal or transdermal therapeutic system comprising a reservoir that contains at least one active substance, an active substance-permeable membrane which delimits the active-substance reservoir, and a closing layer. The closing layer is impermeable to the active substance at a temperature lying below the skin temperature while being permeable at skin temperature and above.